Breast tumor microenvironment: proteomics highlights the treatments targeting secretome.
Tumor secreted substances (secretome), including extracellular matrix (ECM) components, act as mediators of tumor-host communication in the breast tumor microenvironment. Proteomic analysis has emphasized the value of the secretome as a source of prospective markers and drug targets for the treatment of breast cancers. Utilizing bioinformatics, our recent studies revealed global changes in protein expression after the activation of ECM-mediated signaling in breast cancer cells. A newly designed technique integrating a capillary ultrafiltration (CUF) probe with mass spectrometry was demonstrated to dynamically sample and identify in vivo and pure secretome from the tumor microenvironment. Such in vivo profiling of breast cancer secretomes may facilitate the development of novel drugs specifically targeting secretome.
Chen
Shui-Tein
ST
Institute of Biological Chemistry and the Genomics Research Center, Academia Sinica, Taipei, Taiwan.
Pan
Tai-Long
TL
Juan
Hsueh-Fen
HF
Chen
Tai-Yuan
TY
Lin
Yih-Shyan
YS
Huang
Chun-Ming
CM
D017209:Apoptosis / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D005109:Extracellular Matrix / Q000737:chemistry / Q000378:metabolism; D005110:Extracellular Space / Q000378:metabolism*; D005260:Female; D006801:Humans; D016023:Integrins / Q000037:antagonists & inhibitors; D008954:Models, Biological; D011506:Proteins / Q000032:analysis / Q000378:metabolism*; D040901:Proteomics / Q000379:methods*
D016023:Integrins; D011506:Proteins